Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Technology Lead, Discovery Proteomics SRF

Technology Lead, Discovery Proteomics SRF

Iolanda Vendrell

Technologly Lead, Discovery Proteomics SRF

PhD

Iolanda Vendrell joined the Discovery Proteomics Facility at the University of Oxford in 2015, as a senior scientist in Biological Mass Spectrometry. She currently is the Technology Lead.  She studied Biochemistry at the University of Barcelona and holds a PhD in Biochemistry (in the Neuroscience program) by the same University. Her interest in Proteomics and Mass Spectrometry started during her PhD. In 2007, she moved to the UK where she has been working in Proteomics labs in both Academia and Biotech companies. Over the years, Iolanda has developed an extensive expertise in using bottom up-proteomics for general discovery projects, biomarker discovery for clinical samples and post-translational modifications. Currently, one of her interest focuses on developing and implementing high-throughput proteomics platforms for clinical and non-clinical projects.

Recent publications

A cytoplasmic motif in HLA-E that drives clathrin-mediated endocytosis and VCP-associated postendocytic trafficking

Journal article

He W. et al, (2025), Proceedings of the National Academy of Sciences, 122

Acidosis attenuates the hypoxic stabilization of HIF-1α by activating lysosomal degradation

Journal article

White B. et al, (2025), Journal of Cell Biology, 224

ATR-hippo drives force signaling to nuclear F-actin and links mechanotransduction to neurological disorders

Journal article

Chatzifrangkeskou M. et al, (2025), Science Advances, 11

Protocol to profile spatially resolved NLRP3 inflammasome complexes using APEX2-based proximity labeling

Journal article

Liang Z. et al, (2024), STAR Protocols, 5, 103417 - 103417

Cyclin F–EXO1 axis controls cell cycle–dependent execution of double-strand break repair

Journal article

Yang H. et al, (2024), Science Advances, 10

High-throughput mass spectrometry maps the sepsis plasma proteome and differences in patient response

Journal article

Mi Y. et al, (2024), Science Translational Medicine, 16

Oncogenic mutations of KRAS modulate its turnover by the CUL3/LZTR1 E3 ligase complex

Journal article

Damianou A. et al, (2024), Life Science Alliance, 7, e202302245 - e202302245

BLM and BRCA1-BARD1 coordinate complementary mechanisms of joint DNA molecule resolution

Journal article

Tsukada K. et al, (2024), Molecular Cell, 84, 640 - 658.e10

Structural Premise of Selective Deubiquitinase USP30 Inhibition by Small-Molecule Benzosulfonamides

Journal article

O'Brien DP. et al, (2023), Molecular & Cellular Proteomics, 22, 100609 - 100609

USP18 is an essential regulator of muscle cell differentiation and maturation

Journal article

Olie CS. et al, (2023), Cell Death & Disease, 14

Disease-associated KBTBD4 mutations in medulloblastoma elicit neomorphic ubiquitylation activity to promote CoREST degradation

Journal article

Chen Z. et al, (2022), Cell Death & Differentiation, 29, 1955 - 1969

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

Journal article

Ahern DJ. et al, (2022), Cell, 185, 916 - 938.e58

SPRTN protease-cleaved MRE11 decreases DNA repair and radiosensitises cancer cells.

Journal article

Na J. et al, (2021), Cell death & disease, 12